DENGVAXIA
Drug
SANOFI PASTEUR INC.
Total Payments
$129,871
Transactions
23
Doctors
4
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $129,871 | 23 | 4 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $123,415 | 21 | 95.0% |
| Consulting Fee | $6,456 | 2 | 5.0% |
Payments by Type
Research
$123,415
21 transactions
General
$6,456
2 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| CYD12 Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US | SANOFI PASTEUR INC. | $69,340 | 0 |
| CYD51 Evaluation of the Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Administered With or Without Yellow Fever Vaccine in US Adults | SANOFI PASTEUR INC. | $44,385 | 0 |
| CYD01 RANDOMIZED DOUBLE-BLIND PHASE I TRIAL OF THE COMPARATIVE SAFETY TOLERABILITY AND IMMUNOGENICITY OF CHIMERIVAXTm DEN2 A LIVE ATTENUATED MONOVALENT DENGUE 2 VACCINE AND YELLOW FEVER 17D VACCINE | SANOFI PASTEUR INC. | $6,521 | 0 |
| Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5?6 years after completion of the primary series | SANOFI PASTEUR INC. | $1,334 | 1 |
| CYD04 Safety of ChimeriVaXTm Dengue Tetravalent Vaccine in Healthy Adults Aged 18 to 45 Years | SANOFI PASTEUR INC. | $1,000 | 0 |
| Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America | SANOFI PASTEUR INC. | $834.56 | 1 |
Ad
Manufacturing Companies
- SANOFI PASTEUR INC. $129,871
Product Information
- Type Drug
- Total Payments $129,871
- Total Doctors 4
- Transactions 23
About DENGVAXIA
DENGVAXIA is a drug associated with $129,871 in payments to 4 healthcare providers, recorded across 23 transactions in the CMS Open Payments database. The primary manufacturer is SANOFI PASTEUR INC..
Payment data is available from 2019 to 2019. In 2019, $129,871 was paid across 23 transactions to 4 doctors.
The most common payment nature for DENGVAXIA is "Unspecified" ($123,415, 95.0% of total).
DENGVAXIA is associated with 6 research studies, including "CYD12 Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US" ($69,340).